title: Impact of Recent Developments in Lung Cancer on the Practice of Pathology.
abstract: Landmark events in the field of lung cancer in the past year have the potential to significantly alter the practice of pathology. Three key events are (1) approval of payment for low-dose computed tomography screening for lung cancer, (2) publication of an extensively revised World Health Organization classification of lung cancers, and (3) approval of immunohistochemistry based companion diagnostics by the US Food and Drug Administration. We briefly review these milestones in the context of their impact on the practice of pathology.
authors.forename: Philip T
authors.initials: PT
authors.lastname: Cagle
authors.forename: Timothy C
authors.initials: TC
authors.lastname: Allen
authors.forename: Eric H
authors.initials: EH
authors.lastname: Bernicker
authors.forename: Yimin
authors.initials: Y
authors.lastname: Ge
authors.forename: Abida
authors.initials: A
authors.lastname: Haque
authors.affiliation: From the Department of Pathology and Genomic Medicine (Drs Cagle, Ge, Haque, and Barrios).|and Houston Methodist Cancer Center (Dr Bernicker).|Houston Methodist Hospital, Houston, Texas; and the Department of Pathology and Laboratory Medicine, University of Texas Medical Branch, Houston (Dr Allen).
authors.forename: Roberto
authors.initials: R
authors.lastname: Barrios
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D006801:Humans; D007150:Immunohistochemistry / Q000592:standards; D008175:Lung Neoplasms / Q000145:classification / Q000473:pathology*; D010338:Pathology, Clinical / Q000191:economics / Q000379:methods* / Q000639:trends; D014057:Tomography, X-Ray Computed / Q000191:economics; D014481:United States; D014486:United States Food and Drug Administration; D014944:World Health Organization
chemical_list: D014408:Biomarkers, Tumor